Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

NCT03945760 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Allergic Contact Dermatitis

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Wright State Physicians